SavedAdd your journal

Journals / Journal of Health Sciences and Medicine / 2021 / Cilt: 4 - Sayı: 6

Neutrophil-to-lymphocyte ratio in patients with white-coat hypertension

Esin AVŞAR
Gökhan TAZEGÜL
Erkan ÇOBAN
Pages
824–827
Publication Date
2021-09-24
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The mean NLR in the patients-with-WCH group was significantly higher than that in the control group (2.67±0.27 vs. 2.46±0.34, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: White coat hypertension (WCH), a distinct phenotype of hypertension, is defined as elevated office blood pressure (BP) measurements during repeat visits with normal out-of-office BP measurements.
📊
Key Findings & Data:Increased inflammatory processes may explain the underlying pathophysiology of the increased risk for cardiovascular events in WCH; therefore, we evaluated the neutrophil-to-lymphocyte ratio (NLR) of patients with WCH compared with matched normotensive controls.
💡
Conclusion & Impact:Results: The mean NLR in the patients-with-WCH group was significantly higher than that in the control group (2.67±0.27 vs. 2.46±0.34, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:high blood pressure · systemic hypertension · inflammation

Abstract

Introduction: White coat hypertension (WCH), a distinct phenotype of hypertension, is defined as elevated office blood pressure (BP) measurements during repeat visits with normal out-of-office BP measurements. The association of WCH with cardiovascular risk remains unclear; however, current data support an association between untreated WCH and the risk for cardiovascular events, cardiovascular mortality, and all-cause mortality. Increased inflammatory processes may explain the underlying pathophysiology of the increased risk for cardiovascular events in WCH; therefore, we evaluated the neutrophil-to-lymphocyte ratio (NLR) of patients with WCH compared with matched normotensive controls. Material and Method: Forty-five eligible subjects with WCH and 45 age, sex, and BMI matched healthy and normotensive subjects were included in the study. The subjects were assessed by office arterial BP and 24-hour ambulatory BP measurements. An automated blood count analyzer measured the NLR values. Results: The mean NLR in the patients-with-WCH group was significantly higher than that in the control group (2.67±0.27 vs. 2.46±0.34, p

🔖

Cite This Article

AVŞAR, E., TAZEGÜL, G., ÇOBAN, E. (2021). Neutrophil-to-lymphocyte ratio in patients with white-coat hypertension. Journal of Health Sciences and Medicine, Cilt: 4 - Sayı: 6, 824–827. https://ajindex.com/articles/776728

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association Hypertension 2019; 73:e35-e66. Cuspidi C, Sala C, Grassi G, Mancia G. White coat hypertension: to treat or not to treat? Curr Hypertens Rep 2016; 18: 80. Campbell PT, White WB. Utility of ambulatory blood pressure monitoring for the management of hypertension. Curr Opin Cardiol 2017; 32: 365-72.
  2. Huang Y, Huang W, Mai W, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens 2017; 35: 677-88.
  3. Piper MA, Evans CV, Burda BU, Margolis KL, O’Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2015; 162: 192-204.
  4. Franklin SS, Thijs L, Asayama K, et al. Cardiovascular risk in white-coat hypertension. JACC 2016; 68: 2033-43.
  5. Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens 2016; 34: 593-9.
  6. Cohen JB, Denker MG, Cohen DL, Townsend RR. Cardiovascular events and mortality in white coat hypertension. Ann Intern Med 2019; 171: 603-4.
  7. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002; 252: 283-94. Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis 1999; 10: 9–12. Rifai N. C-reactive protein and coronary heart disease: diagnostic and therapeutic implications for primary prevention. Cardiovasc Toxicol 2001; 1: 153-7.
  8. Benzaquen LR, Yu H, Rifai N. High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment. Crit Rev Clin Lab Sci 2002; 39: 459-97. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003; 92: 17K–22K. Ozdogan M, Bozcuk H, Coban E. Low-grade inflammation in white-coat hypertension. Med Sci Monit 2007; 13: CR570-573. Yavuzer H, Cengiz M, Yavuzer S, et al. Procalcitonin and Pentraxin-3: current biomarkers in inflammation in white coat hypertension. J Hum Hypertens 2016; 30: 424-9.
  9. Huang YQ, Jie LI, Chen JY, Tang ST, Huang C, Feng YQ. The relationship between soluble CD40 ligand level and atherosclerosis in white-coat hypertension. J Hum Hypertens 2017; 32: 40-5.
  10. Imtiaz F, Shafique K, Mirza SS, Ay